SCHEMBL8934616

SCHEMBL8934616

CC(=O)Nc1ccc[c]n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
LMNA P02545 1/20 0.47
MAPK8 P45983 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
HSD17B10 Q99714 3/20 0.41
NAPRT Q6XQN6 1/20 0.41
PTK2 Q05397 1/20 0.41
HTT P42858 2/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
ADORA3 P0DMS8 3/20 0.39
ADORA1 P30542 2/20 0.39
ADORA2A P29274 2/20 0.39
MAP4K4 O95819 1/20 0.39
ABL1 P00519 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CDK7 P50613 1/20 0.39
TYRO3 Q06418 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16834690 0.76 PTK2 (0.49) KDM4EHSP90AA1HSP90AB1PTK2GLS
SCHEMBL821844 0.73 KDM4E (0.71) KDM4ELMNAMAPK8L3MBTL1HSP90AA1
SCHEMBL4418275 0.72 GLS (0.58) KDM4ELMNAMAPK8L3MBTL1HSP90AA1
SCHEMBL4757637 0.71 L3MBTL1 (0.48) KDM4ELMNAMAPK8L3MBTL1HSP90AA1
SCHEMBL1430882 0.71 GOT1 (0.50) KDM4ELMNAMAPK8L3MBTL1HSP90AA1
SCHEMBL445712 0.70 KMT2A (0.53) LMNAL3MBTL1HTTMAPTALDH1A1
SCHEMBL4995817 0.69 L3MBTL1 (0.42) KDM4ELMNAMAPK8L3MBTL1HSP90AA1
SCHEMBL29740123 0.68 NPC1 (0.70) KDM4ELMNAL3MBTL1HTTADORA3
SCHEMBL14009931 0.68 GLS (0.50) KDM4ELMNAL3MBTL1HSP90AA1HSP90AB1
SCHEMBL114271 0.68 NPC1 (0.70) KDM4ELMNAL3MBTL1HTTADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036291-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2024-07-16 US claimed
CN-118005611-A Probes for imaging huntingtin CHDI基金会股份有限公司 2024-05-10 CN claimed
US-20210379211-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2021-12-09 US claimed
EP-3186241-B1 PROBES FOR IMAGING HUNTINGTON PROTEIN CHDI FOUNDATION INC (US) 2020-10-07 EP claimed
WO-2017189868-A1 SERINE REPLACEMENT POLYMYXIN ANALOGUES USEFUL AS ANTIBIOTIC POTENTIATORS SPERO OPCO (US) 2017-11-02 WO claimed
WO-2017189866-A1 POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS SPERO OPCO (US) 2017-11-02 WO claimed
US-20170292150-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2017-10-12 US claimed
US-20170281804-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN EVOTEC (UK) LTD. (GB) 2017-10-05 US claimed
EP-3190888-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI Foundation, Inc. (US) 2017-07-19 EP claimed
EP-3186241-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI Foundation, Inc. (US) 2017-07-05 EP claimed
WO-2016033460-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. (US) 2016-03-03 WO claimed
WO-2016033436-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. (US) 2016-03-03 WO claimed
US-20140128373-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-05-08 US claimed
CN-103517710-A Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC 2014-01-15 CN claimed
WO-1996030350-A1 AMIDINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-03 WO claimed
US-12036291-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2024-07-16 US disclosed
CN-118005611-A Probes for imaging huntingtin CHDI基金会股份有限公司 2024-05-10 CN disclosed
WO-1996030350-A1 AMIDINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-03 WO disclosed
US-5360809-A Imidazole compounds and their use as calcium channel blockers NEUROSEARCH A/S (DK) 1994-11-01 US disclosed
US-4138243-A 3,4-DIMETHYL-2-HYDROXY-5-OXO-2,5-DIHYDRO-PYRROLE COMPOUNDS, PESTICIDES, PLANT GROWTH REGULATORS CIBA-GEIGY CORPORATION (US) 1979-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210379211-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 KDM4E 4585/4885LMNA 2021/4885MAPK8 3327/4885
US-20170281804-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 KDM4E 4585/4885LMNA 2021/4885MAPK8 3327/4885
US-20140128373-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 KDM4E 2174/4885LMNA 2215/4885MAPK8 45/4885
US-12036291-B2 Probes for imaging huntingtin protein HTT, HYPK, HSPBP1 KDM4E 4585/4885LMNA 2021/4885MAPK8 3327/4885
US-20170292150-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, FABP7 KDM4E 4674/4885LMNA 1795/4885MAPK8 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.